Pharmaceuticals Divestitures in 2026
Showing 2 transactions.
-
February 4, 2026
- Buyer
- BioSelective Capital Investments, Shayan Enterprises, LLC
- Target
- BioDuro's Irvine drug product development and manufacturing operations (now Forma Life Sciences, Inc.)
- Seller
- BioDuro, Advent International
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Divestiture
BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.
-
January 2, 2026
- Buyer
- SHINE Technologies, LLC
- Target
- Lantheus SPECT business (North Billerica facility)
- Seller
- Lantheus Holdings, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
SHINE Technologies has completed the acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and a portfolio of diagnostic radiopharmaceuticals (TechneLite, Cardiolite, NEUROLITE, Xenon Xe-133). SHINE named Michael Rossi CEO of SHINE SPECT USA, LLC and said the acquisition expands its nuclear medicine manufacturing capabilities and integrates with its Chrysalis Mo-99 production to strengthen isotope supply chain security.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.